Veru Inc. announced the appointment of Erik Swenson, M.D., a world-renowned pulmonologist specializing in critical care, and Robert Schooley, M.D., an accomplished infectious disease physician and researcher, to its Infectious Disease Scientific Advisory Board (SAB) to join David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, who is Chairman of the SAB. Erik Swenson, M.D. is a pulmonologist affiliated with Veterans Affairs Puget Sound Health Care System-Seattle. Dr. Swenson specializes in critical care medicine, internal medicine and pulmonology, with particular concentration in adult acute respiratory distress syndrome (ARDS), pulmonary hypertension, chronic obstructive pulmonary disease, asthma, and tuberculosis for over four decades.

Additionally, he is a Professor of Medicine, Physiology and Biophysics at the University of Washington and previously served as the Chairman of the U.S.FDA'sPulmonary-Allergy Drugs Advisory Committee for 10 years. Dr. Swenson received his M.D. from University of California San Diego School of Medicine. Robert Schooley, M.D., an infectious disease specialist, is affiliated with UC San Diego Health-La Jolla and Hillcrest, where he serves as a Professor in the Division of Infectious Diseases at UC San Diego School of Medicine.

His primary research interests include influenza, global health and international medicine, and the diagnosis and management of infections that cause death and morbidity in resource-limited settings. Notably, Dr. Schooley played a key role as one of the first researchers to describe the humoral and cellular immune responses to HIV infection. He received his M.D. from Johns Hopkins University School of Medicine.

Drs. Swenson and Schooley join David D. Ho, M.D., Chairman of Veru's SAB. David D. Ho, M.D. is the Founding Scientific Director of the Aaron Diamond AIDS Research Center and the Clyde and Helen Wu Professor of Medicine at Columbia University Irving Medical Center, a Member of The National Academy of Medicine, Member of The American Academy of Arts & Sciences, and a Fellow of The American Association for the Advancement of Science.

He received his M.D. from Harvard Medical School and has received fourteen honorary doctorates over the course of his career. In his noteworthy research, Dr. Ho discovered the nature of HIV replication, and the resulting innovative combination therapy remarkably enabled patients to manage this disease. In 1996, Dr. Ho was selected by TIME Magazine as man of the year as a doctor who gives hope to millions in the daunting fight against HIV.

In addition, Dr. Ho is leading a multi-disciplinary team of physicians, and scientists to advance the development of new drugs that target SARS-CoV-2 mutants.